31.   Indeed, biotechnology stocks have rallied with the rest of the market in recent weeks.

32.   Investment professionals have floated competing theories about how biotechnology stocks will fare during these grim days of economic downturn.

33.   It might seem surprising that investors have spurned biotechnology stocks in recent years, because few doubt that medical advances will come from this field.

34.   It was a good day for biotechnology stocks.

35.   Kenneth N. Gilpin interviews him about the prospects of biotechnology stocks.

36.   Jim McCamant thinks there are still fortunes to be made in biotechnology stocks.

37.   Last week, he took some time to talk about the resilience of biotechnology stocks, and their prospects.

38.   Massachusetts stocks fell for a second day, led by Biogen Inc. and Genzyme Corp. amid a downturn in biotechnology stocks.

39.   Maryland stocks fell, pulled down by biotechnology stocks of Human Genome Sciences Inc., Biospherics Inc. and Life Technologies Inc.

40.   Massachusetts stocks rose for the second day, led by Biogen Inc., amid a rally in biotechnology stocks.